Overview

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment period), and exit procedures.
Phase:
Phase 1
Details
Lead Sponsor:
Warner Chilcott
Collaborator:
Sanofi
Treatments:
Etidronic Acid
Risedronate Sodium
Risedronic Acid